Skip to content

DMK PHARMACEUTICALS CORPORATION: 10-Q filed 2023-08-21

What DMK PHARMACEUTICALS CORPORATION reported in its quarterly report filed 2023-08-21 (fiscal Q2 2023): 39 published measures, 104 facts as tagged in accession 0001387131-23-009990.

This filing

Form
10-Q (quarterly report)
Filed
2023-08-21
Fiscal period
fiscal Q2 2023
Accession
0001387131-23-009990 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All DMK PHARMACEUTICALS CORPORATION filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-06-304,749,150USD
At 2022-12-3110,930,840USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-06-3016,244,476USD
At 2022-12-3111,581,605USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-06-30-11,825,326USD
At 2023-03-31-9,681,681USD
At 2022-12-31-808,068USD
At 2022-06-307,042,143USD
At 2022-03-3115,900,281USD
At 2021-12-3125,882,778USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-06-30640,254USD
At 2022-12-311,081,364USD
At 2022-06-308,875,925USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-8,574,122USD91
2023-01-01 to 2023-06-30-17,517,029USD181
2022-04-01 to 2022-06-30-8,397,221USD91
2022-01-01 to 2022-06-30-18,751,836USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-4,116,072USD181
2022-01-01 to 2022-06-30-16,880,385USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2022-01-01 to 2022-06-30381,167USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2023-04-01 to 2023-06-306,945USD91
2023-01-01 to 2023-06-301,459,945USD181
2022-04-01 to 2022-06-3039,847USD91
2022-01-01 to 2022-06-301,194,361USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-06-302,725,000USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-06-30980,069USD181
2022-01-01 to 2022-06-302,549,387USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-06-30-322,081,115USD
At 2022-12-31-304,564,086USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-04-01 to 2023-06-302,569,400shares91
2023-01-01 to 2023-06-302,378,006shares181
2022-04-01 to 2022-06-302,140,224shares91
2022-01-01 to 2022-06-302,138,816shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-04-01 to 2023-06-302,569,400shares91
2023-01-01 to 2023-06-302,378,006shares181
2022-04-01 to 2022-06-302,140,224shares91
2022-01-01 to 2022-06-302,138,816shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-3.4USD/shares91
2023-01-01 to 2023-06-30-7.44USD/shares181
2022-04-01 to 2022-06-30-3.92USD/shares91
2022-01-01 to 2022-06-30-8.77USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-3.4USD/shares91
2023-01-01 to 2023-06-30-7.44USD/shares181
2022-04-01 to 2022-06-30-3.92USD/shares91
2022-01-01 to 2022-06-30-8.77USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-06-301,142,869USD
At 2022-12-311,288,894USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-01-01 to 2023-06-30121,492USD181
2022-01-01 to 2022-06-30-88,799USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-11,304,164USD91
2023-01-01 to 2023-06-30-17,731,845USD181
2022-04-01 to 2022-06-30-8,175,919USD91
2022-01-01 to 2022-06-30-16,089,208USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-06-303,450,698USD
At 2022-12-319,272,150USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2023-04-01 to 2023-06-3046,312USD91
2023-01-01 to 2023-06-30106,344USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-06-3015,007,226USD
At 2022-12-3111,395,866USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2023-06-3011,365,931USD
At 2022-12-317,937,493USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2023-06-30664,358USD
At 2022-12-311,238,778USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-354,449USD91
2023-01-01 to 2023-06-30-689,516USD181
2022-04-01 to 2022-06-30-649,331USD91
2022-01-01 to 2022-06-30-958,399USD181

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2023-04-01 to 2023-06-304,033,083USD91
2023-01-01 to 2023-06-308,815,168USD181
2022-04-01 to 2022-06-304,205,934USD91
2022-01-01 to 2022-06-307,588,630USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-06-302,790,395shares
At 2022-12-312,142,581shares

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-06-30145,909USD
At 2022-12-31317,622USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2023-06-304,013,508USD
At 2022-12-314,665,067USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2023-06-309,674USD
At 2022-12-3152,174USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2023-06-302,200,716USD
At 2022-12-311,510,053USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2023-06-30658,119USD
At 2022-12-311,884,015USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-8,746,819USD91
2023-01-01 to 2023-06-30-17,689,726USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2023-04-01 to 2023-06-3087,000USD91
2023-01-01 to 2023-06-30197,000USD181
2022-04-01 to 2022-06-30368,000USD91
2022-01-01 to 2022-06-30713,000USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2023-04-01 to 2023-06-30463,018USD91
2023-01-01 to 2023-06-30410,017USD181
2022-04-01 to 2022-06-30-257,832USD91
2022-01-01 to 2022-06-30-697,832USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-04-01 to 2023-06-304,300,773USD91
2023-01-01 to 2023-06-301,713,846USD181
2022-04-01 to 2022-06-30-159,535USD91
2022-01-01 to 2022-06-30-2,436,000USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2023-01-01 to 2023-06-302,099,862USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-1,054,058USD181
2022-01-01 to 2022-06-30-815,565USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-574,420USD181
2022-01-01 to 2022-06-30-7,412USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-06-302,972,657USD181
2022-01-01 to 2022-06-30532,465USD181

Inspect the source

Entity
DMK PHARMACEUTICALS CORPORATION / CIK 0000887247
Captured
SEC response SHA-256
cc88d438258619b3d6acde0c3ef806d208e463a48f69c1a0310fac7d087cb187

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000887247.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))